Cargando…

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma

Mutational activation of BRAF is the earliest and most common genetic alteration in human melanoma. Hence, to build a model of human melanoma, we generated mice with conditional melanocyte-specific expression of BRaf(V600E). Upon induction of BRaf(V600E) expression, mice developed benign melanocytic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dankort, David, Curley, David P., Cartlidge, Robert A., Nelson, Betsy, Karnezis, Anthony N., Damsky, William E., You, Mingjian J., DePinho, Ronald A., McMahon, Martin, Bosenberg, Marcus
Formato:	Texto
Lenguaje:	English
Publicado:	2009
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2705918/ https://www.ncbi.nlm.nih.gov/pubmed/19282848 http://dx.doi.org/10.1038/ng.356

Ejemplares similares

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten−/− melanoma
por: Scortegagna, Marzia, et al.
Publicado: (2013)

BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis
por: Sakamoto, Naoya, et al.
Publicado: (2017)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Early differential responses elicited by BRAF(V600E) in adult mouse models
por: Bosso, Giuseppe, et al.
Publicado: (2022)

Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis
por: Liu, Shujing, et al.
Publicado: (2018)

Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation
por: Megías, Javier, et al.
Publicado: (2022)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis
por: Nelson, David S., et al.
Publicado: (2019)

Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF(V600E)-Driven Lung Tumorigenesis
por: Vaishnavi, Aria, et al.
Publicado: (2022)

Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis
por: Nogueira, Cristina, et al.
Publicado: (2010)

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells
por: Jin, Hui, et al.
Publicado: (2013)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Author Correction: Loss of Phd2 cooperates with BRAF(V600E) to drive melanomagenesis
por: Liu, Shujing, et al.
Publicado: (2019)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer
por: Zhang, Zongjing, et al.
Publicado: (2014)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

Diminished WNT → β-catenin → c-MYC signaling is a barrier for malignant progression of BRAF(V600E)-induced lung tumors
por: Juan, Joseph, et al.
Publicado: (2014)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
por: Simpson, Dennis A., et al.
Publicado: (2015)

Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022)

Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification
por: MORENO, Sara, et al.
Publicado: (2021)

ACQUIRED PTEN LOSS MAY MEDIATE DABRAFENIB AND TRAMETINIB RESISTANCE IN BRAF V600E–MUTATED EPITHELIOID GLIOBLASTOMA: A CASE REPORT
por: Ahmed, Abrar, et al.
Publicado: (2023)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors
por: Adashek, Jacob J., et al.
Publicado: (2022)

Mouse models of sporadic thyroid cancer derived from BRAF(V600E) alone or in combination with PTEN haploinsufficiency under physiologic TSH levels
por: Shimamura, Mika, et al.
Publicado: (2018)

BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes
por: Yap, Jiajun, et al.
Publicado: (2023)

c-Myc is Required for BRAF(V600E)-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis
por: Qu, Yiping, et al.
Publicado: (2017)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

MEK inhibitors in non-V600 BRAF mutations and fusions
por: Johnson, Douglas B., et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

BRAF Non-V600 Mutations in Metastatic Colorectal Cancer
por: Liu, Junjia, et al.
Publicado: (2023)

Mutationally-activated PI3’-kinase-α promotes de-differentiation of lung tumors initiated by the BRAF(V600E) oncoprotein kinase
por: van Veen, J Edward, et al.
Publicado: (2019)

BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma
por: Tosuner, Zeynep, et al.
Publicado: (2018)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fp04mvdglrmroaecc9s95890q8